Topics

Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media

08:30 EDT 10 Jun 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that data from OP0201 study C-002 will be...

Other Sources for this Article

Investor Contacts
Timothy McCarthy
LifeSci Advisors, LLC
Tel: 212-915-2564
tim@lifesciadvisors.com

NEXT ARTICLE

More From BioPortfolio on "Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...